Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%

ared to the same period in 2006 (2006: $117.7 million). Expressed in transaction currencies (REPLAGAL is primarily sold in Euros and Pounds sterling) sales increased by 13% due to higher unit sales in Europe and Canada and the continued roll out of REPLAGAL to new countries, including those in Latin America, with REPLAGAL now approved in 41 countries (including Japan). Exchange rate movements against the US dollar accounted for the remaining 9% increase in sales.

ELAPRASE - Hunter syndrome

Sales for the year to December 31, 2007 were $181.8 million (2006: $23.6 million). Sales growth in 2007 was driven primarily by a full year of sales in the US (ELAPRASE was launched in the US in August 2006), sales in Europe (ELAPRASE was launched in several European markets in the first half of 2007), and pre-approval sales in several Latin American markets. ELAPRASE was approved for sale and marketing in Japan in October 2007 and is now approved for marketing and commercial distribution in 37 countries worldwide.

3. Royalties

Royalty revenue increased to $247.2 million for the year ended December 31, 2007 (2006: $242.9 million).

Royalty Highlights

Royalties to Shire Royalty (1) Growth

Product $M %

3TC 145.3 -4

ZEFFIX 41.0 +18

Other 60.9 +6

Total 247.2 +2

(1) Compared with 2006.

3TC - HIV infection and AIDS Royalties from sales of 3TC for the year to December 31, 2007 were $145.3 million, a decrease of 4% compared to the same period in 2006 (2006: $150.9 million). Excluding favorable foreign exchange movements of 4%, there has been a decline of 8% compared to the same period in 2006.

Shire receive

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord ... ) focused on bringing the life saving potential ... that it has reduced its secured debt by a total ... "On April 6th, 2009, Cord Blood America announced it ...
... Precision Engineering), an emerging leader in the ... from fermentation technology, announced that Alex Chu ... of process development. Alex is the ... development for Bristol-Myers Squibb and will lead ...
... available in German . , The ... is able to rapidly ,and efficiently detoxify chemical warfare ... Tokyo subway attacks in 1995. A detailed understanding ,of ... ,necessary for efforts aiming to improve their properties. A ...
Cached Biology Technology:Cord Blood America Says Debt Reduced $4.194 Million in 2009 2Microbia, Inc. Names Alex Chu as Vice President of Process Development 2Structure of enzyme against chemical warfare agents determined 2
(Date:4/15/2014)... Calif. UC Irvine neurobiologists have found that genetically ... into the brains of mice with the symptoms and ... in the journal Stem Cells Research and Therapy ... in two different mouse models. , Alzheimer,s disease, ... associated with accumulation of the protein amyloid-beta in the ...
(Date:4/15/2014)... Md., is home to hundreds of dedicated scientists, ... of the most cutting-edge Earth science innovation and ... innovation has earned a Goddard scientist the 2014 ... and Geography awards the Vega Medal every three ... in the fields of physical geography, exploration or ...
(Date:4/15/2014)... Diana Lados, associate professor of mechanical engineering ... director of the university,s Integrative Materials Design ... achievement awards from leading engineering societies. , ... International, a global association of more than ... the automotive, aerospace, and commercial vehicle industries, ...
Breaking Biology News(10 mins):UCI study finds modified stem cells offer potential pathway to treat Alzheimer's disease 2Goddard scientist receives Vega Medal from King of Sweden 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 2WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 3WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 4WPI's Diana Lados honored by SAE International and Minerals, Metals, and Materials Society 5
... Mo. Approximately 250,000 people in the United States have ... the most common type of the disease, predominantly affecting males. ... their teens and typically die before the age of 30. ... as a possible way to correct the muscle deterioration, but ...
... high blood pressure related to a salty diet? And could ... diseases such as heart failure? A new University of Michigan ... published in the October issue of the Journal of ... of grapes in reducing cardiovascular risk. The effect is thought ...
... Ore. A new study by researchers in Oregon and ... steelhead during their migration to the sea through two large ... remarkably similar despite one major difference. The Columbia River ... However, the researchers point out, there clearly are other differences ...
Cached Biology News:Scientist clears hurdles for muscular dystrophy therapy 2Scientist clears hurdles for muscular dystrophy therapy 3Grapes may aid a bunch of heart risk factors, animal study finds 2Grapes may aid a bunch of heart risk factors, animal study finds 3Grapes may aid a bunch of heart risk factors, animal study finds 4Salmon smolt survival similar in Columbia and Fraser rivers 2Salmon smolt survival similar in Columbia and Fraser rivers 3Salmon smolt survival similar in Columbia and Fraser rivers 4
Anti-ACTH Immunogen: Porcine ACTH conjugated to BSA. Available Date: 38566...
Goat polyclonal to BACE1 ( Abpromise for all tested applications). entrezGeneID: 23621 SwissProtID: P56817...
... Immunogen: Peptide ... encompassing the human, mouse, and ... Accession Number: NM_000314 ... Routinely evaluated by immunoblot. ...
Mouse monoclonal [MN-8C4] to zona radiata ( Abpromise for all tested applications). Antigen: Purified eggshell proteins (zona radiata proteins and small amounts of zona pellucida proteins) from ...
Biology Products: